Ipidacrine: review of efficacy in the authorised indications
Active substance: Ipidacrin
23.05.2025 - Procedure started
Review will evaluate effectiveness in authorised uses and liver safety
EMA’s human medicines committee (CHMP) has started a review of medicines containing ipidacrine. These medicines have been authorised in several EU countries through national procedures and are used in adults to treat different conditions affecting the nervous system.
Further information
For details on the procedure please click on the following link to the homepage of the European Medicines Agency (EMA):